Identification of a d-amino acid decapeptide HIV-1 entry inhibitor

Biochemical and Biophysical Research Communications

Volumn 347, Issue 4, 2006, Pages 909-915

  Boggiano, César ^a   Jiang, Shibo ^b   Lu, Hong ^b   Zhao, Qian ^b   Liu, Shuwen ^b   Binley, James ^a   Blondelle, Sylvie E ^a  

^a TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^b NEW YORK BLOOD CENTER   (United States)

Author keywords

CXCR4 antagonist; d Peptides; Entry inhibitor; HIV 1

Indexed keywords

CD4 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; DC13 PEPTIDE; DEXTRO AMINO ACID; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY; PEPTIDE; STROMAL CELL DERIVED FACTOR 1ALPHA; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; COMBINATORIAL LIBRARY; DRUG IDENTIFICATION; DRUG MECHANISM; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS INHIBITION; VIRUS STRAIN;

CHEMOKINES, CXC; HIV FUSION INHIBITORS; HIV-1; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PEPTIDE LIBRARY; RECEPTORS, CXCR4; T-LYMPHOCYTES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33746366498     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.06.150     Document Type: Article

References (54)

1. De Clercq E. Antiviral drugs in current clinical use. J. Clin. Virol. 30 (2004) 115-133
2. Jiang S., Lin K., Strick N., and Neurath A.R. HIV-1 inhibition by a peptide. Nature 365 (1993) 113
3. Wild C.T., Shugars D.C., Greenwell T.K., McDanal C.B., and Matthews T.J. Peptides corresponding to a predictive α-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA 91 (1994) 9770-9774
4. Lu M., Blacklow S.C., and Kim P.S. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 2 (1995) 1075-1082
5. Chan D.C., Fass D., Berger J.M., and Kim P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89 (1997) 263-273
6. Weissenhorn W., Dessen A., Harrison S.C., Skehel J.J., and Wiley D.C. Atomic structure of the ectodomain from HIV-1 gp41. Nature 387 (1997) 426-430
7. Chan D.C., and Kim P.S. HIV entry and its inhibition. Cell 93 (1998) 681-684
8. Jiang S., Siddiqui P., and Liu S. Blocking viral entry: a complementary strategy for HIV therapy. Drug Discov. Today: Ther. Strateg. 1 (2004) 497-503
9. Kilby J.M., Hopkins S., Venetta T.M., DiMassimo B., Cloud G.A., Lee J.Y., Alldredge L., Hunter E., Lambert D., Bolognesi D., Matthews T., Johnson M.R., Nowak M.A., Shaw G.M., and Saag M.S. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4 (1998) 1302-1307
10. Lazzarin A., Clotet B., Cooper D., Reynes J., Arasteh K., Nelson M., Katlama C., Stellbrink H.J., Delfraissy J.F., Lange J., Huson L., DeMasi R., Wat C., Delehanty J., Drobnes C., and Salgo M. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 348 (2003) 2186-2195
11. Xu L., Pozniak A., Wildfire A., Stanfield-Oakley S.A., Mosier S.M., Ratcliffe D., Workman J., Joall A., Myers R., Smit E., Cane P.A., Greenberg M.L., and Pillay D. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob. Agents Chemother. 49 (2005) 1113-1119
12. Nakashima H., Masuda M., Murakami T., Koyanagi Y., Matsumoto A., Fujii N., and Yamamoto N. Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion. Antimicrob. Agents Chemother. 36 (1992) 1249-1255
13. Murakami T., Nakajima T., Koyanagi Y., Tachibana K., Fujii N., Tamamura H., Yoshida N., Waki M., Matsumoto A., Yoshie O., Kishimoto T., Yamamoto N., and Nagasawa T. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J. Exp. Med. 186 (1997) 1389-1393
14. Fenard D., Lambeau G., Maurin T., Lefebvre J.C., and Doglio A. A peptide derived from bee venom-secreted phospholipase A2 inhibits replication of T-cell tropic HIV-1 strains via interaction with the CXCR4 chemokine receptor. Mol. Pharmacol. 60 (2001) 341-347
15. Doranz B.J., Grovit-Ferbas K., Sharron M.P., Mao S.H., Goetz M.B., Daar E.S., Doms R.W., and O'Brien W.A. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J. Exp. Med. 186 (1997) 1395-1400
16. Zhou N., Luo Z., Luo J., Fan X., Cayabyab M., Hiraoka M., Liu D., Han X., Pesavento J., Dong C.Z., Wang Y., An J., Kaji H., Sodroski J.G., and Huang Z. Exploring the stereochemistry of CXCR4-peptide recognition and inhibiting HIV-1 entry with d-peptides derived from chemokines. J. Biol. Chem. 277 (2002) 17476-17485
17. Eckert D.M., Malashkevich V.N., Hong L.H., Carr P.A., and Kim P.S. Inhibiting HIV-1 entry: discovery of d-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99 (1999) 103-115
18. Houghten R.A., Pinilla C., Appel J.R., Blondelle S.E., Dooley C.T., Eichler J., Nefzi A., and Ostresh J.M. Mixture-based synthetic combinatorial libraries. J. Med. Chem. 42 (1999) 3743-3778
19. Houghten R.A. General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc. Natl. Acad. Sci. USA 82 (1985) 5131-5135
20. Ostresh J.M., Winkle J.H., Hamashin V.T., and Houghten R.A. Peptide libraries: determination of relative reaction rates of protected amino acids in competitive couplings. Biopolymers 34 (1994) 1681-1689
21. 12) sequences. Biochem. J. 301 (1994) 847-853
22. Haertle T., Carrera C.J., Wasson D.B., Sowers L.C., Richman D.D., and Carson D.A. Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2′,3′-dideoxyadenosine derivatives. J. Biol. Chem. 263 (1988) 5870-5875
23. Popovic M., Sarngadharan M.G., Read E., and Gallo R.C. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224 (1984) 497-500
24. Morner A., Bjorndal A., Albert J., Kewalramani V.N., Littman D.R., Inoue R., Thorstensson R., Fenyo E.M., and Bjorling E. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J. Virol. 73 (1999) 2343-2349
25. Scherer W.F., Syverton J.T., and Gey G.O. Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. J. Exp. Med. 97 (1953) 695-710
26. Maddon P.J., Dalgleish A.G., McDougal J.S., Clapham P.R., Weiss R.A., and Axel R. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 47 (1986) 333-348
27. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., Di Marzio P., Marmon S., Sutton R.E., Hill C.M., Davis C.B., Peiper S.C., Schall T.J., Littman D.R., and Landau N.R. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381 (1996) 661-666
28. Toohey K., Wehrly K., Nishio J., Perryman S., and Chesebro B. Human immunodeficiency virus envelope V1 and V2 regions influence replication efficiency in macrophages by affecting virus spread. Virology 213 (1995) 70-79
29. Hsu M., Harouse J.M., Gettie A., Buckner C., Blanchard J., and Cheng-Mayer C. Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120. J. Virol. 77 (2003) 989-998
30. Jiang S., Lin K., and Lu M. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. J. Virol. 72 (1998) 10213-10217
31. Nussbaum O., Broder C.C., and Berger E.A. Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation. J. Virol. 68 (1994) 5411-5422
32. He J., Choe S., Walker R., Di Marzio P., Morgan D.O., and Landau N.R. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J. Virol. 69 (1995) 6705-6711
33. Yee J.K., Miyanohara A., LaPorte P., Bouic K., Burns J.C., and Friedmann T. A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc. Natl. Acad. Sci. USA 91 (1994) 9564-9568
34. Connor R.I., Chen B.K., Choe S., and Landau N.R. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206 (1995) 935-944
35. Jiang S.B., Lin K., and Neurath A.R. Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41. J. Exp. Med. 174 (1991) 1557-1563
36. Zhao Q., Ernst J.T., Hamilton A.D., Debnath A.K., and Jiang S. XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41. AIDS Res. Hum. Retroviruses 18 (2002) 989-997
37. Jiang S., Lin K., Zhang L., and Debnath A.K. A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody. J. Virol. Methods 80 (1999) 85-96
38. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22 (1984) 27-55
39. Zhao Q., Lu H., Schols D., De Clercq E., and Jiang S. Development of a cell-based enzyme-linked immunosorbent assay for high-throughput screening of HIV type 1 entry inhibitors targeting the coreceptor CXCR4. AIDS Res. Hum. Retroviruses 19 (2003) 947-955
40. Bleul C.C., Wu L., Hoxie J.A., Springer T.A., and Mackay C.R. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc. Natl. Acad. Sci. USA 94 (1997) 1925-1930
41. Trkola A., Ketas T.J., Nagashima K.A., Zhao L., Cilliers T., Morris L., Moore J.P., Maddon P.J., and Olson W.C. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J. Virol. 75 (2001) 579-588
42. Braun M., Wunderlin M., Spieth K., Knochel W., Gierschik P., and Moepps B. Xenopus laevis stromal cell-derived factor 1: conservation of structure and function during vertebrate development. J. Immunol. 168 (2002) 2340-2347
43. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
44. Matsuzaki K., Ogino T., Sunazuka T., Tanaka H., and Omura S. Chloropeptins, new anti-HIV antibiotics inhibiting gp120-CD4 binding from Streptomyces sp. II. Structure elucidation of chloropeptin I. J. Antibiot. (Tokyo) 50 (1997) 66-69
45. Debnath A.K., Radigan L., and Jiang S. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. J. Med. Chem. 42 (1999) 3203-3209
46. McKnight A., Wilkinson D., Simmons G., Talbot S., Picard L., Ahuja M., Marsh M., Hoxie J.A., and Clapham P.R. Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent. J. Virol. 71 (1997) 1692-1696
47. Wu L., LaRosa G., Kassam N., Gordon C.J., Heath H., Ruffing N., Chen H., Humblias J., Samson M., Parmentier M., Moore J.P., and Mackay C.R. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J. Exp. Med. 186 (1997) 1373-1381
48. Murakami T., Zhang T.Y., Koyanagi Y., Tanaka Y., Kim J., Suzuki Y., Minoguchi S., Tamamura H., Waki M., Matsumoto A., Fujii N., Shida H., Hoxie J.A., Peiper S.C., and Yamamoto N. Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection. J. Virol. 73 (1999) 7489-7496
49. Morimoto M., Mori H., Otake T., Ueba N., Kunita N., Niwa M., Murakami T., and Iwanaga S. Inhibitory effect of tachyplesin I on the proliferation of human immunodeficiency virus in vitro. Chemotherapy 37 (1991) 206-211
50. Sun L., Finnegan C.M., Kish-Catalone T., Blumenthal R., Garzino-Demo P., La Terra Maggiore G.M., Berrone S., Kleinman C., Wu Z., Abdelwahab S., Lu W., and Garzino-Demo A. Human β-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. J. Virol. 79 (2005) 14318-14329
51. Jiang S. HIV-1-co-receptors binding. Nat. Med. 3 (1997) 367-368
52. Moulard M., Lortat-Jacob H., Mondor I., Roca G., Wyatt R., Sodroski J., Zhao L., Olson W., Kwong P.D., and Sattentau Q.J. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J. Virol. 74 (2000) 1948-1960
53. Dragic T., Trkola A., Lin S.W., Nagashima K.A., Kajumo F., Zhao L., Olson W.C., Wu L., Mackay C.R., Allaway G.P., Sakmar T.P., Moore J.P., and Maddon P.J. Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J. Virol. 72 (1998) 279-285
54. Rabut G.E., Konner J.A., Kajumo F., Moore J.P., and Dragic T. Alanine substitutions of polar and nonpolar residues in the amino-terminal domain of CCR5 differently impair entry of macrophage- and dualtropic isolates of human immunodeficiency virus type 1. J. Virol. 72 (1998) 3464-3468